Alamar Biosciences, Inc.

Alamar Biosciences, Inc. is a proteomics company that develops a proteomic liquid biopsy platform and sells instruments, consumables, and services for the early detection of diseases. The company develops NULISA technology, a proteomics platform designed to detect and quantify protein biomarkers. Alamar Biosciences offers the ARGO high throughput (HT) System, which is a fully automated precision proteomics platform. This system performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across discovery, translational research, and diagnostics. The company's offerings are utilized in research areas such as immunology, neurology, and oncology. Alamar Biosciences serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. Alamar Biosciences, Inc. was incorporated in 2018 and is based in Fremont, California.